AI Meets the Heart: egnite Bets on Clinical Experts to Guide the Future

ALISO VIEJO, CA – June 18, 2026 – In a move that signals a critical maturation point for artificial intelligence in healthcare, the AI firm egnite today announced a significant expansion of its Medical Advisory Board. The company, which specializes in cardiovascular intelligence, has brought on three nationally recognized specialists: Dr. Vijay Iyer, Dr. Daniel Logsdon, and Dr. Andrew Morse. While appointments to advisory boards are common, this one warrants a closer look. It represents a deliberate strategy to anchor powerful algorithms in the bedrock of clinical reality, a fusion of data science and human expertise aimed at solving one of medicine's most persistent and costly challenges: untreated heart disease.

This isn't merely about adding credentials to a letterhead. It's a calculated decision to embed the nuanced perspectives of a leading structural heart interventionalist, a complex-care cardiothoracic surgeon, and a pioneering outcomes researcher directly into the company's development and research DNA. As the healthcare system pivots toward data-driven models, this move underscores a fundamental truth: technology, no matter how intelligent, derives its ultimate value from its application in the hands of those on the front lines of patient care.

More Than a Machine: The Human Hand Guiding the Algorithm

The strategic weight of these appointments lies in the specific expertise each physician brings. Dr. Iyer, Chief of Cardiovascular Medicine at the University at Buffalo, is one of the nation’s most prolific structural heart specialists. Dr. Logsdon is a cardiothoracic surgeon at Eisenhower Health known for tackling complex cases. Dr. Morse directs the Structural Heart and Valvular Disease Center at Ascension Saint Thomas, a leader in clinical trials and innovative therapies. Crucially, all three are not just advisors but active users of egnite's CardioCare® Platform at their respective institutions. Their involvement closes the loop between product development and real-world application.

This direct feedback from practicing super-users is invaluable. It ensures the technology is not developed in a vacuum but is continuously refined by the very challenges and workflows it aims to improve. Joel Portice, CEO of egnite Health, framed the strategy succinctly: "As cardiovascular care becomes increasingly data-driven, the organizations that lead the future of the field will be those that can connect clinical care, operational insight, and real-world evidence." He added, "These appointments strengthen the clinical expertise guiding our platform and reflect our commitment to building solutions grounded in how cardiovascular medicine is actually practiced."

This grounding is what separates promising technology from transformative systems. The board's role is to ensure egnite's platform, which is already deployed in over 800 healthcare facilities, addresses the right clinical questions, integrates seamlessly into complex hospital workflows, and produces insights that are not just statistically significant but clinically actionable.

The Search for the Missing Patient

To understand the impact of egnite's mission, one must first grasp the scale of the problem. Cardiovascular disease remains the leading cause of death in the United States, with nearly half of all adults affected by some form of it. Within this staggering statistic lies a more insidious issue: millions of patients with significant, treatable heart conditions go undiagnosed or fall through the cracks of a fragmented healthcare system. They are the silent majority, often identified only after a catastrophic event like a heart attack or stroke.

egnite's AI-powered platform is designed to find these missing patients. By analyzing millions of de-identified patient records—sifting through echocardiogram reports, lab results, and clinical notes—the system flags individuals who exhibit signs of untreated disease, such as moderate to severe aortic stenosis or mitral regurgitation. But as Dr. Iyer points out, identification is just the beginning. "Identifying untreated patients is only half the equation," he stated. "The harder problem is what happens next — do we actually have the capacity to see them, treat them, and track what happens to them over time? What egnite gives us is visibility into the full patient population that no other tool provides, and the ability to connect that visibility to workflow and planning decisions. That's what turns a data platform into something a cardiovascular program can actually run on."

This transition from a simple data tool to an operational engine is the core of the value proposition. The platform doesn't just raise a flag; it helps orchestrate the subsequent steps, ensuring that an identified patient is routed to the right specialist for timely, guideline-directed care.

Proving the Value: From Proactive Care to Financial Returns

In a healthcare environment increasingly driven by value-based care, demonstrating a tangible return on investment is non-negotiable. Technology must not only improve outcomes but also enhance efficiency. Dr. Logsdon's experience at Eisenhower Health provides a compelling case study. He reported that the institution achieved a 322% ROI using the CardioCare platform, a figure that speaks directly to the operational and financial benefits of a more systematic approach to patient management.

Dr. Logsdon, a surgeon, offers a unique perspective from the end of the clinical decision chain. "Cardiothoracic surgery sits at the end of a long clinical decision chain — and what I see in the OR is a direct reflection of what happened upstream," he explained. "The programs getting this right are moving upstream: prioritizing early detection and intervening at the optimal point in the care journey. At Eisenhower, that shift has been transformative... we expect that to grow as we continue to move from reactive to proactive cardiovascular care." This shift from a reactive, crisis-driven model to a proactive, preventative one is the holy grail of modern healthcare. By identifying disease earlier and managing it more effectively, health systems can prevent costly emergency procedures, reduce hospitalizations, and improve long-term patient health—a clear win for patients, providers, and payers.

The New Frontier: Building a Library of Real-World Evidence

Perhaps the most forward-looking aspect of egnite's strategy is its focus on real-world evidence (RWE). For decades, the gold standard for medical evidence has been the randomized controlled trial (RCT). While essential, RCTs are conducted under ideal conditions with highly selective patient populations. They don't always reflect how a therapy performs in the messy, complex environment of everyday clinical practice with its diverse patient demographics and comorbidities.

This is the gap RWE is poised to fill. By aggregating and analyzing longitudinal data from its registry of nearly 14 million de-identified patient records, egnite can generate insights into how cutting-edge therapies perform across the full spectrum of patients. This is where Dr. Morse's expertise becomes particularly salient. A principal investigator on numerous landmark structural heart trials, he understands the limitations of traditional research and the immense potential of large-scale, real-world data.

"The therapies available for structural heart and valvular disease have advanced tremendously over the past decade," Dr. Morse noted. "What has not kept pace is the real-world evidence needed to understand how these therapies perform across the full spectrum of patients treated in everyday clinical practice. egnite's registry helps close that gap by providing longitudinal, real-world data at scale—creating insights that can improve patient care, inform clinical decision-making, and accelerate innovation across structural heart medicine." This capability transforms a clinical management tool into a powerful research engine, one that can help refine treatment guidelines, accelerate device innovation, and ultimately create a learning health system where every patient interaction contributes to a deeper understanding of cardiovascular disease.